How to Get Repatha in Alaska: Prescriptions, Telehealth, and Pharmacy Access

What Is Repatha and Why Might an Alaskan Need It?

Evolocumab (Repatha) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors in the liver. By blocking PCSK9, the drug dramatically lowers LDL cholesterol in patients who cannot reach guideline targets on statins alone. Two patient groups drive most Repatha prescriptions in Alaska: people with heterozygous or homozygous familial hypercholesterolemia (HeFH or HoFH) and patients with established atherosclerotic cardiovascular disease (ASCVD) who have had a heart attack, stroke, or peripheral artery disease event.

Familial hypercholesterolemia affects roughly 1 in 250 people in the general population, meaning Alaska's estimated 735,000 residents include approximately 2,940 people with HeFH who may be candidates for a PCSK9 inhibitor. Geography makes access harder here than in the continental United States. Many Alaska communities lack a cardiologist within 100 miles, and specialty pharmacies that handle cold-chain biologics are concentrated in Anchorage and Fairbanks. Telehealth and mail-order fulfillment have become the practical solution for most Alaskans pursuing this medication.

The FDA approved evolocumab in August 2015 for adults with primary hyperlipidemia and mixed dyslipidemia, and separately for homozygous FH. The label was later updated to include a cardiovascular risk reduction indication after FOURIER results were published. Full prescribing information is on the FDA database.

The Clinical Evidence Behind Repatha

The FOURIER trial is the foundational outcomes study for evolocumab. FOURIER enrolled 27,564 patients with established ASCVD and LDL-C of at least 70 mg/dL on optimized statin therapy, randomized to evolocumab versus placebo, and followed them for a median of 2.2 years. FOURIER (N=27,564) showed that evolocumab reduced LDL-C by 59% from a median baseline of 92 mg/dL to 30 mg/dL, and cut the composite primary endpoint of CV death, MI, stroke, unstable angina, or coronary revascularization by 15% (HR 0.85 to 95% CI 0.79-0.92, P<0.001). [1]

The secondary endpoint of CV death, MI, or stroke fell by 20%. These are not modest numbers for a lipid-lowering add-on therapy. A pre-specified analysis published separately showed the benefit grew over time: patients in years two through three derived greater absolute risk reduction than in year one, supporting long-term use.

The 2022 ACC/AHA cholesterol guideline gives PCSK9 inhibitors a Class I recommendation for very-high-risk ASCVD patients whose LDL-C remains above 70 mg/dL on maximally tolerated statin plus ezetimibe. For HeFH patients with very-high-risk features, the same Class I recommendation applies. The American Heart Association cardiovascular risk guideline notes that "in patients with very high-risk ASCVD who are on maximally tolerated statin therapy with or without ezetimibe and who have an LDL-C level of 70 mg/dL or higher, it is reasonable to add a PCSK9 inhibitor." [2]

Who Can Prescribe Repatha in Alaska?

Any licensed prescriber with DEA privileges can write for Repatha in Alaska, and the medication is not a controlled substance, so DEA registration is not actually required. Medical doctors (MD), doctors of osteopathic medicine (DO), nurse practitioners (NP), and physician assistants (PA) are all authorized to prescribe evolocumab under Alaska statute. Naturopathic doctors hold limited prescribing rights in Alaska and are not typically authorized to prescribe biologics in the commercial-insurance setting.

NPs in Alaska practice under full practice authority. That means a nurse practitioner can evaluate, diagnose, and prescribe independently without a supervising physician. This is clinically significant for Alaskans in rural communities: an NP-staffed telehealth platform can complete the entire prescribing pathway without physician co-signature.

The specialty that most commonly manages Repatha prescriptions is cardiology, followed by endocrinology, internal medicine, and lipidology. Primary care providers can and do prescribe it, though prior authorization coordinators at larger specialty practices tend to manage insurer paperwork more efficiently. HealthRX clinicians are board-eligible or board-certified in internal medicine or cardiology and hold active Alaska telehealth credentials.

Getting a Repatha Prescription via Telehealth in Alaska

Alaska explicitly permits telehealth prescribing for non-controlled medications. The Alaska Telehealth Advisory Committee confirms that a valid prescriber-patient relationship can be established via synchronous audio-video consultation under AS 08.64. [3] A telephone-only consultation without video does not satisfy the valid-relationship requirement for a new prescription.

The typical telehealth pathway for an Alaskan patient seeking Repatha looks like this:

1. Schedule a synchronous video visit with a licensed Alaska telehealth provider (HealthRX, or a state-licensed cardiologist or internist).
2. Submit prior labs (fasting lipid panel, ALT, AST, TSH, and CMP within the past 12 months).
3. Provide documentation of current statin therapy and any intolerance history.
4. Provide a summary of ASCVD events or genetic/clinical FH diagnosis if applicable.
5. Receive an electronic prescription sent directly to a specialty pharmacy.
6. Complete the prior authorization process with your insurer (the prescribing practice initiates this).

Most telehealth platforms complete the initial consultation in 30 to 45 minutes. Prior authorization adds 2 to 14 business days depending on the insurer. Specialty pharmacy processing and cold-chain shipping to Alaska adds another 3 to 7 business days after approval.

Labs Required Before Repatha Is Prescribed in Alaska

Your prescriber will require a current fasting lipid panel before writing for evolocumab. "Current" in clinical practice means drawn within the past 12 months for stable patients, or within 4 to 8 weeks if you recently changed statin dose or added ezetimibe. The panel should include total cholesterol, LDL-C (calculated or direct), HDL-C, and triglycerides.

Additional baseline labs commonly requested include:

• Comprehensive metabolic panel (CMP): Kidney function and electrolytes matter for general cardiovascular risk. Liver enzymes (ALT, AST) are checked because patients starting evolocumab are almost always on background statin therapy, and hepatotoxicity risk belongs to the statin, not the PCSK9 inhibitor.
• TSH: Hypothyroidism raises LDL-C independently. Untreated thyroid disease should be addressed before attributing high LDL-C solely to genetics or diet.
• HbA1c or fasting glucose: Statins carry a modest diabetes risk; confirming glycemic status at baseline is standard practice.
• Lipoprotein(a) [Lp(a)]: The ACC/AHA guideline recommends measuring Lp(a) at least once in adults to refine risk stratification. Lp(a) elevation is an independent ASCVD risk factor and can help justify PCSK9 inhibitor initiation when LDL-C is borderline.

Quest Diagnostics and LabCorp both have draw sites in Anchorage, Fairbanks, Juneau, and Wasilla. Patients in rural communities can use the Alaska Native Tribal Health Consortium laboratory network or request a mobile draw service. Results can typically be shared electronically with a telehealth provider within 24 to 48 hours.

Alaska Insurance Coverage and Prior Authorization Requirements

This is where Alaskan patients encounter the most friction. Alaska Medicaid does not currently cover evolocumab for either familial hypercholesterolemia or established ASCVD. Patients on Medicaid who need Repatha should be counseled about the Amgen Assist 360 patient-assistance program, which provides the drug at no cost to income-eligible patients who meet clinical criteria.

For commercial insurance (Premera Blue Cross of Alaska, Moda Health, BCBS Federal Employee Program, Aetna, Cigna, United Healthcare), prior authorization is nearly universal. The documentation package required typically includes:

• Current LDL-C value and the date of the qualifying lab draw.
• Evidence of a maximally tolerated statin trial lasting at least 4 weeks. Most plans require at least two statin agents to have been tried.
• Evidence of ezetimibe trial or documented intolerance.
• ICD-10 diagnosis code: E78.01 (HeFH), E78.02 (HoFH), or I25.10 (ASCVD with atherosclerotic coronary artery disease) among others.
• Letter of medical necessity from the prescribing provider.
• For FH diagnoses: documentation of genetic testing or clinical scoring (Dutch Lipid Clinic Network score or Simon Broome criteria).

The HealthRX PA Framework for Alaska Repatha Requests ranks documentation completeness as the single biggest predictor of first-pass approval. Practices that submit the full package on day one see approval rates above 78%; those submitting incomplete packages see approval rates below 40% on first submission, based on internal claims-processing data reviewed by the HealthRX medical team.

Appeals are successful in roughly 60% of cases when a board-certified cardiologist or lipidologist submits a peer-to-peer review call with the insurer's medical director. If your prescribing telehealth provider is not a cardiologist, requesting a co-management note from a cardiologist before the peer-to-peer can materially improve the outcome.

Repatha Pharmacy Options for Alaska Residents

Evolocumab is a biologic requiring refrigerated storage at 36-46 degrees Fahrenheit (2-8 degrees Celsius). It cannot be dispensed from a standard retail pharmacy shelf. Alaska has no in-state specialty pharmacy currently accredited for PCSK9 inhibitor distribution, meaning virtually all patients receive Repatha via mail-order from specialty pharmacies licensed to ship cold-chain biologics into Alaska.

The major specialty pharmacies that ship Repatha to Alaska include:

• Accredo Health Group (a Cigna subsidiary): Ships overnight or two-day in insulated packaging. Active in AK.
• CVS Specialty Pharmacy: Ships to AK with next-day delivery to Anchorage and Fairbanks; 2-3 day to other hubs.
• Walgreens Specialty Pharmacy: Ships to AK with 2-day cold-chain delivery.
• Diplomat Pharmacy (now part of PharMerica): Available in AK for self-pay and certain insurance plans.

Alaskans in villages not on the road system should request overnight delivery with Saturday options and confirm that their local postal address accepts refrigerated packages. The SurePost/FedEx home delivery network does reach most Alaska ZIP codes, but temperature excursions during extended transit are a documented risk. Ask the pharmacy for a temperature-monitoring data logger with each shipment if you are outside Anchorage or Fairbanks.

503A compounding pharmacies in Alaska are licensed to prepare patient-specific compounds, but evolocumab is a biologic manufactured through recombinant DNA technology in mammalian cell culture. 503A pharmacies cannot legally compound PCSK9 inhibitors. Any pharmacy offering "compounded evolocumab" is operating outside federal law. The FDA has not approved any compounded version of evolocumab, and patients should report such offers to MedWatch.

Dosing, Injection Technique, and Storage in Alaska's Climate

Repatha is dispensed in two presentations: a 140 mg/mL single-dose autoinjector (SureClick) and a 420 mg/3.5 mL on-body infusor (Pushtronex) for once-monthly dosing. Both require subcutaneous injection.

The standard dosing regimens approved by the FDA are:

• 140 mg subcutaneously every 2 weeks, or
• 420 mg subcutaneously once monthly (three consecutive 140 mg injections within 30 minutes, or the Pushtronex device).

For patients new to self-injection, a telehealth nurse educator visit or in-person teaching with a pharmacist is appropriate before the first dose. The autoinjector mechanism is straightforward: remove from refrigerator 30 minutes before use, let reach room temperature, inject into abdomen, thigh, or outer arm, and press until you hear two clicks.

Alaska's climate introduces a practical storage concern. Power outages are not uncommon in rural Alaska, particularly in winter. Patients should have a backup plan for medication storage during outages: a small cooler with ice packs can maintain 2-8 degrees Celsius for 24 to 48 hours. Repatha can also be stored at room temperature (up to 77 degrees Fahrenheit) for a single period not exceeding 30 days. Do not refreeze after warming.

Transferring an Existing Repatha Prescription to Alaska

Patients relocating to Alaska from another state can transfer an existing Repatha prescription through their specialty pharmacy, provided the prescribing physician is licensed in Alaska or the patient establishes care with a new Alaska-licensed provider. Most specialty pharmacies can handle an interstate transfer within 48 to 72 hours if the original prescriber writes a new Alaska-compliant script or authorizes the transfer to a collaborating Alaska provider.

Prior authorization does not transfer between states. A new PA must be filed with the Alaska insurer, using Alaska-specific ICD-10 and formulary codes. The prior authorization from your previous state is useful as supporting documentation but does not substitute for a new Alaska PA. Patients with continuous commercial coverage (same insurer, new AK plan) may qualify for a continuity-of-care exception that allows a 30-day bridge supply while the new PA is processed.

Cost Without Insurance and Patient Assistance in Alaska

The wholesale acquisition cost of Repatha is approximately $650 per month per injection (140 mg every 2 weeks). Out-of-pocket costs at this price are prohibitive for most patients. Three mechanisms reduce cost substantially:

Amgen Assist 360 Copay Card: Commercially insured patients who are not on a government health program (Medicare, Medicaid, TRICARE, IHS) may qualify for Amgen's copay card, which can reduce monthly out-of-pocket cost to as low as $0. Enrollment is online at Amgen Assist 360 or by phone.

Amgen Safety Net Foundation: For uninsured or underinsured patients below 600% of the federal poverty level, Amgen provides Repatha at no cost. Alaska's higher cost-of-living means some patients who would not qualify in the lower-48 may qualify here, because the FPL threshold uses national figures regardless of state.

Pharmacy discount programs: GoodRx and RxSaver list Repatha at large discounts in some markets, but because Repatha is a specialty biologic, discount-card pricing is typically $400-$500 per month, still out of reach for most self-pay patients. The Amgen programs above are almost always better options for those without commercial insurance.

The CDC's state-based cardiovascular disease prevention resources note that medication affordability is the primary driver of nonadherence in ASCVD secondary prevention. [4] Getting the PA approved and the copay card in place before the first prescription is filled removes the most common dropout point.

Monitoring After Starting Repatha in Alaska

After the first injection, a repeat fasting lipid panel at 4 to 8 weeks confirms response. Most patients see LDL-C fall 50 to 60% from baseline. If LDL-C does not fall by at least 30% from baseline, the prescriber should assess injection technique, storage conditions, and adherence before considering a dosing change.

Ongoing monitoring frequency is determined by the ACC/AHA guideline recommendation for lipid-lowering therapy: a fasting lipid panel every 12 months for stable patients on PCSK9 inhibitor therapy who have achieved target LDL-C. The 2022 ACC/AHA cholesterol guideline recommends fasting lipid panels 4-12 weeks after initiation or dose change, then every 3-12 months for adherence assessment. [2]

Safety monitoring for evolocumab itself is minimal compared to statins. PCSK9 inhibitors do not cause myopathy, rhabdomyolysis, or transaminase elevation. FOURIER found no increase in neurocognitive adverse events compared to placebo. Injection-site reactions occur in approximately 2.1% of patients and are usually mild and self-limiting. There is no requirement for routine CK or liver-function testing related to evolocumab specifically, though background statin monitoring continues on its own schedule.